Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Given Average Rating of “Strong Buy” by Analysts

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) has been given a consensus rating of “Strong Buy” by the five research firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a buy recommendation and three have given a strong buy recommendation to the company.

Several research firms recently issued reports on CURLF. Zacks Research raised shares of Curaleaf from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 14th. Citigroup reiterated a “buy” rating on shares of Curaleaf in a research note on Thursday.

Curaleaf Stock Up 6.6%

Shares of Curaleaf stock traded up $0.55 during trading on Thursday, hitting $8.90. 51,593 shares of the stock traded hands, compared to its average volume of 312,614. The stock has a market cap of $2.08 billion, a P/E ratio of -22.82 and a beta of 1.56. The company has a fifty day moving average price of $7.04 and a two-hundred day moving average price of $7.68. Curaleaf has a twelve month low of $4.56 and a twelve month high of $15.15. The company has a debt-to-equity ratio of 1.05, a quick ratio of 0.74 and a current ratio of 1.56.

Curaleaf (OTCMKTS:CURLF) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of ($0.20) by $0.25. The firm had revenue of $340.10 million for the quarter, compared to analyst estimates of $332.00 million. Curaleaf had a negative net margin of 7.76% and a negative return on equity of 8.11%. Equities research analysts predict that Curaleaf will post -0.31 EPS for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.